Janux Therapeutics, Inc. Common Stock (JANX) is a publicly traded Healthcare sector company. As of July 5, 2026, JANX trades at $15.54 with a market cap of $947.70M and a P/E ratio of -8.45. JANX moved +6.14% today. Year to date, JANX is +12.36%; over the trailing twelve months it is -35.41%. Its 52-week range spans $12.12 to $71.71. Analyst consensus is strong buy with an average price target of $31.00. Rallies surfaces JANX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Janux Therapeutics Rises 6% on Peer Veraxa Cancer Milestone: Janux Therapeutics shares jumped 6% after the biotech sector rallied on news that a peer’s lead cancer program reached a key development milestone. Peer Veraxa’s trial progress also drove gains in MGNX (+1.95%) and CGEM (+2.03%), while Veraxa stock surged 18.26%.
| Metric | Value |
|---|---|
| Price | $15.54 |
| Market Cap | $947.70M |
| P/E Ratio | -8.45 |
| EPS | $-1.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $71.71 |
| 52-Week Low | $12.12 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $13.73M |
| Net Income | $-114.48M |
| Gross Margin | 0.00% |
14 analysts cover JANX: 0 strong buy, 12 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $31.00.